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IMMUNOLOGY
Chronic HIV Infection Is Associated with Upregulation
of Proinflammatory Cytokine and Chemokine and Alpha
Defensin Gene Expression in Colorectal Mucosa
Jennifer Mait-Kaufman,1 Esra Fakioglu,1 Pedro M.M. Mesquita,1,2 Julie Elliott,3
Yungtai Lo,4 and Rebecca Pellett Madan1
Abstract
HIVmay induce gastrointestinal (GI)mucosal immune dysregulation similar to inflammation observed in ulcerative
colitis (UC). Colorectal biopsies from healthy controls (N= 12) and from participants with HIV (N= 20) or UC
(N= 9) were subjected to real time (RT)-PCR for selected cytokines, chemokines, antimicrobial peptides, Toll-like
receptors, and inflammatory signaling and epithelial barrier proteins. HIV long terminal repeat relative copy number
(RCN) in HIV participant biopsies was quantified by RT-PCR. Mean interleukin (IL)-6mRNA levels did not differ
significantly between HIV and UC participants ( p= 0.48) but were significantly higher relative to control mRNA
levels only for HIV participants ( p= 0.03). Mean IL-8 and human defensin (HD) 5mRNA levels were similar
between HIV and UC participants ( p= 1.0 and p= 0.35, respectively) and were significantly greater in both groups
relative to controls ( p< 0.05 for all). Human beta-defensin (HBD)-2mRNA levels were higher in UC relative to
HIV and control participants ( p< 0.01 for both). Conversely, HBD-1mRNA levels were downregulated in UC vs.
HIV participants ( p= 0.01). Mediator gene expression did not differ significantly between HIV participants with
detectable (N= 10) or nondetectable (N= 10) plasma viral loads. TissueHIV relative copy number (RCN) correlated
with plasma viral load (r= 0.88, p< 0.01) but not with mediator mRNA levels. The results of this study indicate that
both chronic HIV infection and UC are associated with similar patterns of IL-6, IL- 8, and HD5 expression in
colorectal biopsy tissue. These findings suggest overlapping mechanisms for GI mucosal inflammation in these two
illnesses and merit further investigation in larger studies.
Introduction
HIV-induced inflammation and tissue injury in thegastrointestinal tract may impact viral pathogenesis by
potentiating local HIV replication and recruitment of HIV
target cells. Colorectal biopsy tissue from individuals with
chronic HIV infection may not show evidence of significant
cellular inflammation by qualitative histology, as concomi-
tant CD4 + T-lymphocyte depletion and CD8 + T-lymphocyte
influx may result in an overall normocellular appearance.1–3
However, prior studies have shown evidence of cellular in-
flammation by flow cytometry in intestinal biopsies from
HIV-infected participants1 and have described upregulation
of proinflammatory cytokines and chemokines in intestinal
biopsies from HIV-infected individuals compared to unin-
fected individuals,1,4,5 with the highest levels of inflamma-
tory cytokines observed in those with high levels of local HIV
replication.5 The majority of participants in past studies
lacked gastrointestinal symptoms. Use of antiretroviral
therapy (ART) and average plasma viral loads varied among
participants in these prior studies, thus it is difficult to eval-
uate the impact of these variables on mucosal inflammation.
However, mucosal inflammation is abrogated by ART in
some studies, suggesting a direct association between HIV
replication and inflammation.5–7
Alterations of soluble immune mediators at the intestinal
mucosa in the setting of HIV may overlap with those ob-
served in patients with ulcerative colitis (UC) and Crohn’s
disease.1,8 One prior study identified upregulated expression
of inflammatory cytokines and chemokines in intestinal
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biopsies from participants with HIV or inflammatory bowel
disease (IBD).1 Although biopsies from HIV-infected par-
ticipants in this study appeared similar to those from healthy
controls by qualitative histology, gene expression for the HIV
coreceptors CCR5 and CXCR4 and for the chemokines reg-
ulated on activation, normal T cell expressed and secreted
(RANTES), macrophage inflammatory protein (MIP)-1b,
and MIP-1a was upregulated relative to healthy controls and
was similar between UC and HIV-infected participants.
Altered expression of genes integral to intestinal barrier
integrity is well described in IBD9 and has also been described
in studies of HIV-infected individuals,2,6,10,11 although prior
studies have not directly compared intestinal barrier gene ex-
pression between these two groups. Loss of barrier integrity in
the setting of IBD orHIVmay promotemicrobial translocation
and potentiate inflammation, thus exacerbating colitis and viral
dissemination.12–16 Dysregulated intestinal mucosa expression
of Toll-like receptors (TLR), inflammatory signaling proteins,
and antimicrobial peptides such as defensins may also con-
tribute to altered mucosal immunity in the setting of HIV or
IBD.17–19 Altered gene expression of human beta-defensin
(HBD)-2 and HBD-317 and multiple TLRs20 has been de-
scribed in intestinal biopsies from IBD patients. Altered en-
teric defensin and TLR expression in the setting of HIV has
been suggested based on the findings of animal studies21,22 but
has not been studied in HIV-infected humans.
Few human studies have characterized alterations of sol-
uble immune mediators at the intestinal mucosa that occur in
the setting of HIV or have directly compared the changes that
may occur in both HIV and IBD. Furthermore, the association
between HIV replication and gastrointestinal antimicrobial
peptides has not been well characterized in human models. A
more thorough investigation of the similarities between IBD
and HIV intestinal pathogenesis could expand our under-
standing of how mucosal inflammation in the setting of HIV
contributes to systemic inflammation and disease progression
and could inform the development of novel antiinflammatory
therapies for both IBD and HIV.
To address these gaps, we used real time (RT)-PCR to
quantify mRNA for a select panel of mucosal mediators in
colorectal biopsies collected from participants with HIV in-
fection, from participants with active UC disease (‘‘positive
inflammatory’’ control group) and from healthy participants
(‘‘negative inflammatory’’ control group). Mediators assessed
by PCR were selected for their potential role in inhibiting or
promoting local inflammation or for their relevance to intes-
tinal barrier integrity. Biopsy samples from HIV-infected
participants were also subjected to PCR for HIV long terminal
repeat (LTR) gene expression to evaluate the relationship be-
tween local viral replication and inflammation. We hypothe-
sized that chronic HIV infection is associated with intestinal
mucosal inflammation similar to that described in UC and that
we would observe similar levels of inflammatory gene ex-
pression when comparing biopsies from HIV-infected partic-
ipants to biopsies from UC participants.
Materials and Methods
Participants
This study was approved by the UCLA Office of the Hu-
man Research Protection Program Institutional Review
Board, and use of deidentified samples was approved by the
Albert Einstein College of Medicine Institutional Review
Board. Participants were recruited through the Mucosal
Immunology Core Laboratory at UCLA, provided written
informed consent, and underwent endoscopic evaluation.
Colorectal biopsy tissue was obtained as previously de-
scribed.1 To augment the study’s sample size, colorectal bi-
opsy samples from two healthy individuals and from five
individuals with active UC were obtained from OriGene
Technologies, Inc. (Rockville, MD).
Histological scoring
Histology scores for all samples (UCLA and OriGene)
were assigned by a single blinded gastrointestinal pathologist
according to a validated colonic inflammation scoring system
that ranged from a score of 1 (normal histology) to 6 (severely
abnormal histology with destruction of epithelium and min-
imal cellular elements) (Fig. 1).3,23 For UCLA-recruited
participants, biopsies were mounted on mesh screens, fixed in
10% formalin, and embedded in paraffin. Sections (7 lm)
were stained with hematoxylin and eosin and examined under
light microscopy. Two slides with three sections per biopsy
were evaluated at 4· and 10 · power. This histology scoring
system was also applied to photographed slides from the
OriGene samples.
Total RNA extraction and RT-PCR amplification
to quantify mRNA
Total RNA was extracted from deidentified and homoge-
nized UCLA biopsy tissue using an Absolutely RNA RT-
PCR Miniprep Kit (Strategene, La Jolla, CA). RNA (200 ng)
was then reverse transcribed with a High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster City,
CA). RT-PCR amplification was performed in duplicate
using an ABI PRISM 7000 detection system and analyzed
using sequence detector software. PCR cycling conditions
were as follows: 1 cycle, 50C for 2min; 1 cycle, 95C for
15min; 45 cycles, 95C for 10 s; and 1 cycle, 60C for 1min.
Gene expression levels were calculated as 2ddCt (where Ct
indicates cycle threshold) using large ribosomal protein
(RPLPO) as the endogenous control. Gene expression levels
for UC and HIV-infected participants were compared to
healthy control participants. Specimens with undetectable
RNA levels were attributed a Ct value of 45.
The following commercially available probes (Applied
Biosystems, Foster City, CA) were used for all specimens:
human SLPI (Hs00268204_m1), human beta-defensin 1
(HBD-1) (Hs00174765_m1), human beta-defensin 2 (HBD-2)
(Hs00175474_m1), human beta-defensin 3 (HBD-3)
(Hs00218678_mL), human defensin 5 (HD5) (Hs00360716_
mL), human neutrophil peptides 1–3 (HNP1-3) (Hs00234383_
mL), (Hs00175474_m1), interleukin 6 (IL-6) (Hs00174131_m1),
interleukin 8 (IL-8) (Hs00174103_m1), interleukin 17 (IL-17)
(Hs00174383), interleukin 1b (IL-1b) (Hs00174097_mL),
tumor necrosis factor-a (TNF-a) (Hs00174128_m1), toll-like
receptor 2 (TLR2) (Hs00152932_m1), toll-like receptor 4
(TLR4) (Hs00152939_mL), toll-like receptor 5 (TLR5)
(Hs00152825_mL), toll-like receptor 9 (TLR9) (Hs00152973_
mL), myeloid differentiation primary response gene (88)
(MyD88) (Hs00182082_m1), tight junction protein 1 (TJP1)
(Hs01551876_mL), CHUK (IKK alpha) (Hs00175141_m1),
and ribosomal large protein subunit (RPLPO) (4333761F).
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HIV RNA quantitation in biopsy tissue collected from
HIV-infected participants was interpolated using a calibra-
tion curve generated from serial dilutions of cell lysate pre-
pared from U1 cells, a monocytic cell line infected with
HIV.24 HIV relative copy number (RCN) was calculated as
the ratio between HIV LTR and RPLPO copy numbers as
previously described.25
Statistical analysis
Differences in participant demographics between groups
were compared using analysis of variance (ANOVA) or
t-tests for continuous variables and chi-square or Fisher’s
exact tests for categorical variables. Gene expression levels
of mediators were log10 transformed to reduce skewness.
Differences in mediators between HIV, UC, and control
groups were compared using one-way ANOVA, followed by
Bonferroni correction for post hoc pairwise comparisons.
Spearman correlation coefficients were used to assess cor-
relations between HIV plasma viral load, HIV RCN in biopsy
tissue, and mRNA of immune mediators. All analyses were
performed using GraphPad Prism version 6 (San Diego,
CA.). All tests for significance were two-sided, and a value of
p < 0.05 was considered significant.
Results
Participants
Forty-one study participants provided a total of 41 colo-
rectal biopsy samples and included 20 individuals with HIV
infection, nine individuals with active UC, and 12 healthy
control participants (Table 1). Ten HIV-infected participants
had nondetectable (< 50 copies/ml) plasma viral load (PVL)
(HIVNDVL). Ten HIV-infected participants had detectable
PVL (HIVDVL), with a mean– standard deviation (SD) viral
load of 4.38– 0.53 log10 copies/ml (Table 1). Nine of 10
HIVNDVL participants and six of 10 HIVDVL participants re-
ceived ART at the time of biopsy ( p= 0.30). HIVNDVL par-
ticipants had a significantly higher mean peripheral CD4+ T
lymphocyte count compared to HIVDVL participants (692.4
cells/ll– 351.7 vs. 301.6– 232.3, p< 0.001). Participant
medications, including ART regimens, are detailed in Table 2.
Histological scoring
All healthy control participants had normal (grade 1) his-
tological scores on biopsy (Table 1). All UC participants had
moderate (grade 4) (N = 6) or severe (grade 5–6) (N = 3)
histological scores (Table 1). All HIVNDVL participants had
normal scores. Nine of the 10 HIVDVL participants had nor-
mal or mildly abnormal (grade 2–3) scores. UC participants
were significantly more likely to have a moderate or severe
histological score when compared to all HIV participants or
to control participants ( p< 0.001 for both). The proportions
of subjects with normal vs. abnormal histological scores did
not differ significantly between all HIV participants and
control participants ( p = 1.0). Neutrophil counts were ob-
tained from histology sections from seven UC, 11 HIV, and
five control participants; samples from UC participants were
more likely to have neutrophil infiltrates compared to
FIG. 1. Histological grading scale
(grades 1–6) illustrated using repre-
sentative hematoxylin–eosin-stained
sections of colonic mucosa. Grade 1:
Intact epithelium and lamina propria.
No structural abnormality. Grade 2:
Detatched epithelium but intact
lamina propria. Chronic inflamma-
tory cell infiltrates. Grade 3: De-
tached epithelium and disaggregated
lamina propria. Neutrophil infiltrates
in lamina propria. Grade 4: Detached
epithelium and disaggregated lamina
propria with > 30% karyorrhexis.
Neutrophil infiltrates in epithelium.
Grade 5: Detached epithelium and
disaggregated lamina propria with
> 75% karyorrhexis and crypt de-
struction. Grade 6: Epithelium lost
and minimal cellular remnants, with
mostly structural elements remain-
ing and erosions or ulcerations
present. Biopsy samples scored as
grade 1 were categorized as normal.
Samples scored as grades 2–3 were
categorized as having mild changes,
grade 4 samples were categorized as
moderate, and grades 5–6 were cat-
egorized as severe.
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samples from HIV or control participants ( p = 0.03). Five of
the seven samples from UC participants had neutrophil in-
filtrates [mean 41.08 neutrophils per high power field
(HPF) – 30.92], while only two samples from HIV partici-
pants had identifiable neutrophils (mean 0.7 neutrophils per
HPF – 0.71), and no neutrophils were identified in samples
from control participants.
IL-6 and IL-8 expression in HIV-infected participants
did not differ significantly from UC participants and was
significantly upregulated relative to controls
Mean IL-6mRNA levels were modestly but not signifi-
cantly higher in HIV-infected compared to UC participants
(1.12 – 1.17 vs. 0.49 – 1.13, respectively; p = 0.48) and were
significantly upregulated relative to controls only for HIV-
infected participants ( p = 0.03) (Fig. 2a). Mean IL-8mRNA
levels were similar between all HIV-infected and UC par-
ticipants (1.14 – 0.77 vs. 1.05 – 1.02, respectively; p = 1.0)
and were significantly higher relative to controls for both
HIV-infected ( p = 0.02) and UC participants ( p = 0.04) (Fig.
2b). When HIV-infected patients were then stratified by PVL,
mean IL-8 and IL-6mRNA levels were significantly higher
only in the HIVDVL group relative to controls ( p= 0.01 for
IL-6, p = 0.02 for IL-8). Expression of IL-1b, IL-17, and TNF
did not differ significantly between participants with HIV,
UC, or controls ( p> 0.05 for all, data not shown).
Expression of human defensin 5, but not of human
beta-defensins-1 or -2, was similar between HIV-
infected and UC participants
Mean HD5mRNA levels were similar between all HIV
and UC participants (1.92– 1.69 vs. 2.27 – 1.37, respectively;
p = 0.35) and were significantly upregulated in both groups
relative to controls ( p = 0.004 for UC, p = 0.003 for all HIV)
(Fig. 2c). Again, when HIV-infected participants were
stratified by PVL, only the HIVDVL group had significantly
higher mean levels of HD5mRNA relative to controls
( p = 0.002). HBD-1 expression was significantly down-
regulated in UC relative to all HIV-infected participants
( - 0.79 – 0.64 vs. 0.32 – 0.85, respectively; p = 0.01), and
Table 1. Participant Demographics
UC a N = 9 All HIV N= 20 Controls N = 12 p value
Sex
Male, number (%) 7 (77.8) 19 (95) 10 (83.3) 0.36
Female, number 2 (22.2) 1 (5) 2 (16.7)
Age, years
Mean – SDb 39.3 – 14 45.4 – 10.3 42.5 – 12.1 0.29
Race
White, number (%) 9 (100) 15 (75) 6 (50) 0.15
Nonwhite, number 0 (0) 5 (25) 6 (50)
Histology scorec
Number with normal to mild (%) 0 (0) 19 (95) 12 (100) < 0.001 (UC vs. HIV)
Number with moderate to severe (%) 9 (100) 1 (5) 0 (0) < 0.001 (UC vs. controls)
1.0 (HIV vs. controls)
HIV-infected participantsd
Characteristic HIVDVL N = 10 HIVNDVL N = 10 p value
Plasma viral load
Mean log10 copies –SD 4.4 – 0.5 n/a n/a
CD4 + T-lymphocyte count
Mean cells/ll– SD 301.6 – 232.3 692.4 – 351.7 < 0.001
ARTe at the time of biopsy
Yes, number (%) 6 (60) 9 (90) 0.30
No 4 (40) 1 (10)
Number of years from HIV diagnosisf n = 6 n = 7
Mean – SD 17.5 – 5.2 10.1– 3.3 0.01
Histology score
Normal, number (%) 5 (50) 10 (100) 0.03
Mild 4 (40) 0 (0)
Moderate 0 (0) 0 (0)
Severe 1 (10) 0 (0)
aUlcerative colitis.
bStandard deviation.
cNormal histology score= grade 1, mild histology score= grade 2–3, moderate histology score= grade 4, severe histology score= grade 5–6.
dHIV-infected subjects were dichotomized according to detectable plasma viral load (HIVDVL) or nondetectable ( < 50 copies/ml)
(HIVNDVL) plasma viral load.
eAntiretroviral therapy.
fTime from diagnosis was not available for all participants.
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HBD-1mRNA levels were significantly higher in the HIVNDVL
group relative to participants with UC (Fig. 2d). In contrast,
mean HBD-2mRNA levels were significantly higher in UC
participants (3.02 – 2.54) relative to all HIV-infected (0.41 –
1.54, p = 0.002) and control participants ( p = 0.001) (Fig. 2e).
A trend was noted toward higher mean HNP 1–3mRNA
levels in UC compared to HIV-infected participants (1.35 –
1.03 vs. 0.23 – 1.42, respectively), but no significant differ-
ence was identified between UC, HIV, and control partici-
pants ( p= 0.05) (data not shown). No significant differences
were observed between groups for HBD-3mRNA ( p > 0.05
for all, data not shown).
Mean MyD88 expression was significantly higher in UC
compared to all HIV-infected participants (0.25– 0.31 vs.
0.11– 0.38, p= 0.03), although expression for both groups was
similar to that observed in healthy control participants ( p> 0.05
for both) (Fig. 2f). No statistically significant differences be-
tween groups were observed for expression of CHUK, TJP-1,
or SLPI ( p> 0.05 for all, data not shown) or for TLR2, TLR4,
TLR5, and TLR9 ( p> 0.05 for all, data not shown).
HIV relative copy number is highest in biopsies
from participants with detectable plasma viral loads
Mean HIV RCN from biopsy tissue was significantly higher
in HIVDVL compared to HIVNDVL participants (0.04– 0.01 vs.
4.7e-005– 2.67e-005, p= 0.01) and correlated positively with
plasma viral load (r= 0.88, p< 0.01). We identified no signif-
icant correlations between plasma viral loads and mediator
gene expression in biopsy tissue or between biopsy tissue HIV
RCN and mediator gene expression (data not shown). No
significant differences in mediator gene expression were ob-
served when participants were stratified by HIVDVL vs.
HIVNDVL or by ART vs. no ART use (data not shown).
Discussion
In this cohort of chronically infected HIV participants, we
observed patterns of gastrointestinal mucosal mediator ex-
pression that were similar to those observed in participants
with active UC, although expression of beta-defensins dif-
fered between the two groups. While the majority of HIV-
infected participants received ART and had normal to mildly
abnormal histology scores, soluble mediator expression in
HIV-infected participants differed significantly from control
participants. Together, these findings suggest evidence of GI
mucosal inflammation in the setting of HIV and underscore
the findings of prior studies in which biopsies from HIV-
infected participants were found to have increased expression
of inflammatory chemokines and evidence of cellular in-
flammation by flow cytometry and immunohistochemistry,
despite normal qualitative histology scores.1,3
Gene expression of proinflammatory IL-6 and IL-8 did not
differ significantly between HIV-infected and UC partici-
pants, and both IL-6 and IL-8 were significantly upregulated
in HIV-infected participants relative to controls. IL-6 upre-
gulation in the GI mucosa of HIV-infected individuals is
consistent with prior studies, which found that IL-6 upre-
gulation persisted after initiation of ART26 and in the setting
of undetectable mucosal viral load.5 We did not observe a
significant difference in levels of IL-6 or IL-8mRNA be-
tween HIVDVL and HIVNDVL participants or between par-
ticipants who received or did not receive ART. Thus, ART
and peripheral viral suppression may not fully suppress IL-6
and IL-8 gene expression, and chronic upregulation may
lead to ongoing mucosal inflammation, target cell recruit-
ment, direct stimulation of HIV replication, and lymphocyte
depletion.27–29
To our knowledge, our study is the first to examine de-
fensin and TLR expression in the gastrointestinal mucosa of
HIV-infected individuals. Although HD5 expression was
similar between HIV-infected and UC participants, HBD-1
and -2 expression differed between these two groups. Inter-
estingly, HBD-2mRNA levels in HIV-infected participants
were significantly lower than those observed in UC partici-
pants. HBD-2 exhibits activity against HIV-1 in a human oral
epithelial cell culture model.30 HIV infection is thought to























4 Infliximab, prednisone 4 No medications 4 Lamivudine/zidovudine, efavirenz, acyclovir
5 Unknown 5 No medications 5 No medications
6 5-ASA 6 Emtricitabine/tenofovir DF
/efavirenz
6 Raltegravir, lopinavir/ritonavir, etravirine
7 5-ASA 7 No medications 7 Lamivudine, didanosine, nevirapine, stavudine
8 Fish oil 8 No medications 8 Lamivudine/zidovudine, saquinavir, nelfinavir
9 5-ASA, prednisone, 6-MP 9 Lopinavir/ritonavir,
tenofovir DF, abacavir
9 Lamivudine, stavudine, tenofovir DF
10 Lopinavir/ritonavir, lamivudine 10 Lamivudine, stavudrine, efavirenz
HIV-infected participants were stratified according to detectable plasma viral load (HIVDVL) vs. nondetectable plasma viral load
(HIVNDVL).
5-ASA, 5-aminosalicylic acid; AZA, azathioprine; 6-MP, 6-mercaptopurine; DF, disoproxil fumarate.
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induce expression of HBD-2 by epithelial cells, and signifi-
cant upregulation of HBD-2 gene expression was observed in
the oral epithelial mucosa (but not the genital tract mucosa)
of HIV-exposed, seronegative individuals.31 Our small
sample size may have limited our ability to detect significant
upregulation of HBD-2 gene expression in HIV-infected
participants, especially because only 10 participants had
detectable plasma viral loads and evidence of local HIV
replication by HIV RCN. As the majority of our HIV-infected
participants received ART, an alternative theory is that use of
ART abrogates upregulation of HBD-2 in the setting of HIV.
In contrast, the alpha-defensin HD5 is thought to be con-
stitutively expressed by intestinal Paneth cells and by geni-
tourinary tract epithelial cells.32,33 Thus, upregulation of
HD5 in both HIV-infected and UC participants relative to
controls is intriguing. One prior study identified higher con-
centrations of HD5 by immunoblot from urethral lavage from
individuals with gonococcal or chlamydial urethritis, sug-
gesting that mucosal inflammation may induce HD5 secre-
tion.34 HD5 may exert anti-HIV activity in the serum-free
environment of the intestinal lumen35 but the in vivo roles of
both alpha- and beta-defensins against viral infection and
replication remain unclear, and elevated levels could also
promote inflammation. The role of alpha- and beta-defensins
as protective antimicrobial peptides vs. promoters of mucosal
inflammation requires investigation in larger cohorts of in-
dividuals with HIV or UC and may provide insight into the
pathogenesis of these two disease states.
Along with crypt architecture destruction and plasmacel-
lular infiltrates, neutrophil infiltrates are included in the his-
tological criteria for diagnosis of inflammatory bowel
disease.36–38 Neutrophil infiltrates were identified in histo-
logical sections from UC participants; only scant neutrophils
were identified in available histological sections from HIV
participants and were not identified in sections from control
participants. Neutrophil degranulation in UC biopsy samples
may provide a rationale for the observed trend of increased
HNP 1–3 gene expression in UC participants. MyD88-
dependent signaling may induce neutrophil recruitment in the
setting of acute intestinal infection;39 however, MyD88 gene
FIG. 2. mRNA for interleukin (IL)-6, IL-8, human defensin (HD)5, human b defensin (HBD)-1, HBD-2, and MyD88 was
quantified from biopsy tissue by real time (RT)-PCR. mRNA levels were log-transformed, expressed relative to large ribo-
somal protein (RPLPO), and compared across groups by one-way analysis of variance (ANOVA) followed by Bonferroni
correction for post hoc pairwise comparisons. As a secondary analysis, HIV-infected participants (all HIV) were stratified by
detectable (HIVDVL) vs. nondetectable (HIVNDVL) plasma viral load; mRNA levels did not differ significantly for any
mediator between the HIVDVL and HIVNDVL groups ( p> 0.05 for all). (a) Mean IL-6mRNA levels did not differ significantly
between ulcerative colitis (UC) and all HIV participants ( p= 0.48) but were significantly higher in all HIV participants vs.
controls. (b) IL-8mRNA levels were similar between UC and all HIV participants ( p= 1.0) and differed significantly in both
groups from those observed in controls. (c) Mean HD5mRNA levels were similar between UC and all HIV participants
( p= 1.0) but were significantly higher in both groups relative to controls. (d) Mean HBD-1mRNA levels were significantly
lower in UC compared to all HIV participants. (e) Mean HBD-2 levels were significantly higher in UC compared to all HIV
and control participants. (f) Mean MyD88mRNA levels were significantly higher in UC compared to all HIV participants.
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expression was relatively low across all three groups and was
similar between UC and control participants.
Although we found that HIV RCN in biopsy tissue corre-
lated positively and significantly with plasma viral load, we
did not identify significant correlations between HIV RCN
and mediator gene expression. The majority of HIV-infected
participants received ART, which limited our ability to assess
how mediator expression may vary between those who do or
do not receive ART. ART may impact the soluble mucosal
immune environment by reducing gastrointestinal antigen
challenge and infection and reducing local viral replication,
thus permitting T-lymphocytes to reestablish mucosal ho-
meostasis. One prior study described a reduction in gastro-
intestinal mucosal cytokine expression after initiation of
ART and suggested that those with nondetectable mucosal
viral loads on ART had downregulation of mucosal cytokine
expression relative to healthy controls.5 Additional studies
are needed to address the impact of different antiretroviral
therapy regimens on mucosal inflammation. A more com-
prehensive understanding of the relationship between sys-
temic and mucosal inflammation and replication could
impact the development of therapies to eradicate HIV res-
ervoirs. Furthermore, identification of common pathways of
mucosal inflammation among HIV-infected and IBD patients
could lead to novel antiinflammatory therapies that offer
therapeutic benefit for both diseases.
Acknowledgments
The authors wish to thank Dr. Peter Anton and Dr. Betsy
C. Herold for their editorial assistance, Dr. Yanhua Wang for
her histopathology assistance, and Dr. Gloria C. Preza for her
assistance in figure preparation. The authors also wish to thank
the Mucosal Immunology Core of the UCLA Center for AIDS
Research (CFAR) (NIH/NIAID AI-028697) for providing the
biopsy samples and demographic and histology data utilized in
this study. This work was supported by NIH/NIAID K23AI-
089271 (to R.P.M.), by NIH/NIAID T32 AI070117 (awarded
to the Albert Einstein College of Medicine), and by the Albert
Einstein College of Medicine/Montefiore Medical Center
CFAR (NIH/NIAID AI-051519). The funders had no role in
the study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Author Disclosure Statement
No competing financial interests exist.
References
1. Olsson J, Poles M, Spetz AL, et al.: Human immunodefi-
ciency virus type 1 infection is associated with significant
mucosal inflammation characterized by increased expres-
sion of CCR5, CXCR4, and beta-chemokines. J Infect Dis
2000;182(6):1625–1635.
2. Sankaran S, George MD, Reay E, et al.: Rapid onset of
intestinal epithelial barrier dysfunction in primary human
immunodeficiency virus infection is driven by an imbal-
ance between immune response and mucosal repair and
regeneration. J Virol 2008;82(1):538–545.
3. McGowan I, Elliott J, Cortina G, et al.: Characterization of
baseline intestinal mucosal indices of injury and inflam-
mation in men for use in rectal microbicide trials (HIV
Prevention Trials Network-056). J Acquir Immune Defic
Syndr 2007;46(4):417–425.
4. McGowan I, Radford-Smith G, and Jewell DP: Cytokine
gene expression in HIV-infected intestinal mucosa. AIDS
1994;8(11):1569–1575.
5. McGowan I, Elliott J, Fuerst M, et al.: Increased HIV-1
mucosal replication is associated with generalized mucosal
cytokine activation. J Acquir Immune Defic Syndr
2004;37(2):1228–1236.
6. Epple HJ, Schneider T, Troeger H, et al.: Impairment of the
intestinal barrier is evident in untreated but absent in sup-
pressively treated HIV-infected patients. Gut 2009;58(2):
220–227.
7. Verhoeven D, Sankaran S, Silvey M, and Dandekar S:
Antiviral therapy during primary simian immunodeficiency
virus infection fails to prevent acute loss of CD4+ T cells
in gut mucosa but enhances their rapid restoration through
central memory T cells. J Virol 2008;82(8):4016–4027.
8. Brenchley JM and Douek DC: HIV infection and the gas-
trointestinal immune system. Mucosal Immunol 2008;
1(1):23–30.
9. Kinugasa T, Akagi Y, Yoshida T, et al.: Increased claudin-
1 protein expression contributes to tumorigenesis in ulcer-
ative colitis-associated colorectal cancer. Anticancer Res
2010;30(8):3181–3186.
10. Estes JD, Harris LD, Klatt NR, et al.: Damaged intestinal
epithelial integrity linked to microbial translocation in
pathogenic simian immunodeficiency virus infections.
PLoS Pathog 2010;6(8):e1001052.
11. Epple HJ, Allers K, Troger H, et al.: Acute HIV infection
induces mucosal infiltration with CD4+ and CD8+ T
cells, epithelial apoptosis, and a mucosal barrier defect.
Gastroenterology 2010;139(4):1289–1300.
12. Sandler NG and Douek DC: Microbial translocation in HIV
infection: Causes, consequences and treatment opportuni-
ties. Nat Rev Microbiol 2012;10(9):655–666.
13. Brenchley JM and Douek DC: The mucosal barrier and
immune activation in HIV pathogenesis. Curr Opin HIV
AIDS 2008;3(3):356–361.
14. Suzuki T, Yoshinaga N, and Tanabe S: Interleukin-6 (IL-6)
regulates claudin-2 expression and tight junction perme-
ability in intestinal epithelium. J Biol Chem 2011;286(36):
31263–31271.
15. Swidsinski A, Ladhoff A, Pernthaler A, et al.: Mucosal
flora in inflammatory bowel disease. Gastroenterology
2002;122(1):44–54.
16. d’Ettorre G, Paiardini M, Zaffiri L, et al.: HIV persistence
in the gut mucosa of HIV-infected subjects undergoing
antiretroviral therapy correlates with immune activation
and increased levels of LPS. Curr HIV Res 2011;9(3):
148–153.
17. Wehkamp J, Harder J, Weichenthal M, et al.: Inducible and
constitutive beta-defensins are differentially expressed in
Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis
2003;9(4):215–223.
18. Wehkamp J, Harder J, Weichenthal M, et al.: NOD2
(CARD15) mutations in Crohn’s disease are associated
with diminished mucosal alpha-defensin expression. Gut
2004;53(11):1658–1664.
19. Brenchley JM, Price DA, Schacker TW, et al.: Microbial
translocation is a cause of systemic immune activation in
chronic HIV infection. Nat Med 2006;12(12):1365–1371.
20. Stanislawowski M, Wierzbicki PM, Golab A, et al.: De-
creased Toll-like receptor-5 (TLR-5) expression in the
GI MUCOSAL INFLAMMATION IN HIV INFECTION 621
mucosa of ulcerative colitis patients. J Physiol Pharmacol
2009;60(Suppl 4):71–75.
21. Zaragoza MM, Sankaran-Walters S, Canfield DR, et al.:
Persistence of gut mucosal innate immune defenses by
enteric alpha-defensin expression in the simian immuno-
deficiency virus model of AIDS. J Immunol 2011;186(3):
1589–1597.
22. Klatt NR, Funderburg NT, and Brenchley JM: Microbial
translocation, immune activation, and HIV disease. Trends
Microbiol 2013;21(1):6–13.
23. Geboes K, Riddell R, Ost A, et al.: A reproducible grading
scale for histological assessment of inflammation in ulcer-
ative colitis. Gut 2000;47(3):404–409.
24. Folks TM, Justement J, Kinter A, et al.: Cytokine-induced
expression of HIV-1 in a chronically infected promonocyte
cell line. Science 1987;238(4828):800–802.
25. Mesquita PM, Rastogi R, Segarra TJ, et al.: Intravaginal
ring delivery of tenofovir disoproxil fumarate for preven-
tion of HIV and herpes simplex virus infection. J Anti-
microb Chemother 2012;67(7):1730–1738.
26. Schulbin H, Bode H, Stocker H, et al.: Cytokine expression
in the colonic mucosa of human immunodeficiency virus-
infected individuals before and during 9 months of anti-
retroviral therapy. Antimicrob Agents Chemother 2008;
52(9):3377–3384.
27. Poli G, Bressler P, Kinter A, et al.: Interleukin 6 induces
human immunodeficiency virus expression in infected
monocytic cells alone and in synergy with tumor necrosis
factor alpha by transcriptional and post-transcriptional
mechanisms. J Exp Med 1990;172(1):151–158.
28. Lane BR, Lore K, Bock PJ, et al.: Interleukin-8 stimulates
human immunodeficiency virus type 1 replication and is a
potential new target for antiretroviral therapy. J Virol
2001;75(17):8195–8202.
29. Haase AT: Targeting early infection to prevent HIV-1
mucosal transmission. Nature 2010;464(7286):217–223.
30. Quinones-Mateu ME, Lederman MM, Feng Z, et al.: Hu-
man epithelial beta-defensins 2 and 3 inhibit HIV-1 repli-
cation. AIDS 2003;17(16):F39–48.
31. Zapata W, Rodriguez B, Weber J, et al.: Increased levels of
human beta-defensins mRNA in sexually HIV-1 exposed
but uninfected individuals. Curr HIV Res 2008;6(6):531–
538.
32. Bevins CL and Salzman NH: Paneth cells, antimicrobial
peptides and maintenance of intestinal homeostasis. Nat
Rev Microbiol 2011;9(5):356–368.
33. Selsted ME and Ouellette AJ: Mammalian defensins in the
antimicrobial immune response. Nat Immunol 2005;6(6):
551–557.
34. Porter E, Yang H, Yavagal S, et al.: Distinct defensin
profiles in Neisseria gonorrhoeae and Chlamydia tracho-
matis urethritis reveal novel epithelial cell-neutrophil in-
teractions. Infect Immun 2005;73(8):4823–4833.
35. Wilson SS, Wiens ME, and Smith JG: Antiviral mecha-
nisms of human defensins. J Mol Biol 2013;425(24):4965–
4980.
36. Morson B: Rectal and colonic biopsy in inflammatory bo-
wel disease. Am J Gastroenterol 1977;67(5):417–426.
37. Surawicz CM and Belic L: Rectal biopsy helps to distin-
guish acute self-limited colitis from idiopathic inflamma-
tory bowel disease. Gastroenterology 1984;86(1):104–113.
38. Jenkins D, Balsitis M, Gallivan S, et al.: Guidelines for the
initial biopsy diagnosis of suspected chronic idiopathic
inflammatory bowel disease. The British Society of Gas-
troenterology Initiative. J Clin Pathol 1997;50(2):93–105.
39. Jarchum I, Liu M, Shi C, et al.: Critical role for MyD88-
mediated neutrophil recruitment during Clostridium diffi-




Albert Einstein College of Medicine
1300 Morris Park Avenue
Forchheimer 702D
Bronx, New York 10461
E-mail: rebecca.madan@einstein.yu.edu
622 MAIT-KAUFMAN ET AL.
